RESULTS
• An ad-hoc search of the literature was conducted to identify existing checklists. Items from these checklists were extracted and critically reviewed.
• Recommendations from NICE [1, 2] as well as existing NICE submissions and corresponding comments from the evidence review groups (ERG) were used to develop the checklist, which was then tested by statisticians to assess the clarity and the accuracy of each item.
• The checklist was then tested independently by health economists and/or pharmacists not trained in NMA on the basis of a NICE submission in type 2 diabetes mellitus. The definition of statistical terms was provided to them to ensure the best comprehension of the checklist (Table 1 ).
• Finally, the answers and feedback from the testers were reviewed and the checklist was updated accordingly.
• To develop a checklist to assess the quality of an NMA in the context of a submission to NICE.
• This checklist is intended to be comprehensible and easy-to-use by non-statisticians to assess whether an NMA is suitable for a submission to NICE and/or to populate cost-effectiveness models within the context of NICE requirements.
[1] http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the- Meta-analysis: Quantitative synthesis of results from several studies (usually randomised controlled trial) to obtain an overall estimate of the relative effect of treatments. The studies are assumed to be comparable in terms of population of interest.
Direct comparison (or pairwise meta-analysis)
Comparison between two treatments (A vs. B) using head-to-head trials 
Adjusted indirect comparison
Comparison between two treatments (A vs. B) which have not been trialled against each other. The adjusted indirect comparison is conducted using relative treatment effect through a common comparator (C)
Mixed treatment comparisons (MTC) (Or Bayesian network meta-analysis)
Comparison between more than 2 treatments (A, B, C and D), which combines both the direct and the indirect evidence (i.e. mixed comparison). This analysis is based on a network of evidence.
Bayesian analyses
• Unknown parameters (e.g. "true" treatment effects) are treated probabilistically and estimated based on simulations • Outputs from Bayesian analyses include probability distributions (i.e. "posterior" distributions) from which are derived mean/median and 95% credible intervals (interpretation: There is a 95% probability for the true treatment effect to be inside the credible interval) Frequentist analyses • Based on the assumption that unknown parameters (e.g. "true" treatment effects) are fixed and data are a repeated random sample.
• Outputs from frequentist analyses include p-values and 95% confidence intervals (interpretation: Based on a large number of repeated samples, 95% of confidence intervals would include the "true" treatment effect) Heterogeneity: Variability in relative treatment effects between trials within pairwise comparisons Inconsistency: Discrepancy between the direct and the indirect evidence within closed loops Example:
• Direct evidence between A vs. B • Indirect evidence through the comparator C In case of inconsistency, the direct effect of A vs. B is statistically significantly different from the indirect effect of A vs. B (through C). definition of the decision problem, methods of analysis and presentation of results, issues specific to network synthesis, and embedding the synthesis in a probabilistic cost-effectiveness model. It has been developed for analysts who review evidence syntheses in the context of decision making.
• The ISPOR task force published a 26-item questionnaire to help decision makers assess the relevance and credibility of indirect comparisons and network meta-analyses. Domains included in the checklist consisted of evidence base, analysis, reporting quality & transparency, interpretation and conflict of interest.
• Many items from these checklists require prior statistical knowledge, such as "If there are multi-arm trials, have the correlations between the relative treatment effects been taken into account?" [3] ; "Was a valid rationale provided for the use of random-effects or fixed-effect models?" [4] • Some items from both checklists were subjective, e.g. "Are there apparent or potential differences between trials in their patient populations, albeit within the target population?" [3] ; "Are the conclusions fair and balanced?" [4] • As a consequence, these checklists sometimes lack clarity and may be difficult to use for nonstatisticians.
• The PRISMA checklist includes 32 items which focus on the reporting of systematic reviews and NMAs in scientific journals. This checklist was based on experts consensus and was recently extended to incorporate items specific to methods and results from NMAs. This checklist has been developed for analysts who work on the reporting of NMAs in scientific publications but not to assess the quality of the NMA.
• Additionally the ISPOR and PRISMA checklists are not fully in line with the NICE guidelines. If additional comparators were included in the meta-analysis, was it justified?
If treatments of interest were not included in the meta-analysis, was it justified?
Were treatment doses and/or durations selected based on the UK license?
Were all treatments connected to the network by at least one trial?
Study population Was study population defined based on the NICE scope?
Outcomes of interest
Was the choice of the analysed outcomes justified according to the NICE scope?
Methods

Study selection
Was a systematic literature review conducted according to the NICE guidelines?
The aim of this check-list is to assess the validity of the meta-analysis, assuming that the systematic literature review was of good quality and according to the NICE guidelines.
Statistical model
Was the statistical method a non-naïve method (adjusted indirect comparison, Bayesian network meta-analysis…)?
Was the rule to select a fixed vs. random effects model reported?
Assumption for the base case analysis
Were background therapies and/or concomitant therapies accounted for?
Were class effects assumption (including pooled doses) made and justified?
Was the approach to account for different time points acceptable (i.e. outcomes collected at similar time points or justification provided for pooling different time points)?
Heterogeneity and inconsistency assessment
Were the population characteristics at baseline compared across trials?
Were the heterogeneity and inconsistency assessed from both a statistical and clinical standpoints?
Were treatment effect modifiers identified and their distribution assessed across trials?
Sensitivity analyses
Were sensitivity analyses conducted to assess the robustness of the results?
If the answer to the previous question is yes, were sensitivity analyses conducted to account for trials potentially sources of heterogeneity and/or inconsistency?
Reporting of results Overview of our checklist (Table 2) • A total of 25 items were included in our checklist, which covered the definition of study question, methods and reporting of results.
• The checklist focused on the NMA approach and was based on the assumption that the study selection was conducted in line with the NICE guidelines (i.e. systematic literature review).
[1]
Results from the testers of the checklist • Seven health economists and/or pharmacists tested the checklist independently.
• Tests were followed by a qualitative discussion with each tester.
• Testers gave identical answers for the majority of questions.
• Some answers were confused due to a lack of clarity in the NMA (in particular how heterogeneity and inconsistency were assessed).
Limitations of the checklist
• This checklist aims to assess the validity of an NMA assuming that the literature search conducted to select the trials was in line with the NICE guidelines.
• Some items from the checklist are based on the reporting of the statistical approach (e.g. "Was the rule to select a fixed vs. random effects model reported?"). However, the validity of the statistical approach is not assessed as part of the checklist, e.g. whether the rule used to select a fixed vs. random effects is in line with the NICE guidelines.
• Some items from the checklist are subjective, e.g. " Were background therapies and/or concomitant therapies accounted for?".
• Network meta-analyses (NMA) are recommended by NICE to compare all relevant competing interventions in the absence of head-to-head trials. [1,2] • The results of such analyses are then used to populate the sections relating to the treatment effectiveness and to inform the development of a cost-effectiveness models. The preparation and writing of the submission are often prepared by market access managers and/or clinical experts, who may not be trained specifically in NMA.
• This project aimed to prepare a checklist to assess the quality of an NMA, suitable for use by people who may not be trained in the statistical methods used for these projects.
• Our checklist can be used by non-statisticians to assess the quality of an NMA and help prepare NICE submissions.
• Our checklist does not lead to a score quantifying the validity of an NMA. However, it should be noted that an NMA can potentially be highly criticised by NICE if some of our checklist items are not fulfilled, such as "Was the statistical method a non-naïve method (adjusted indirect comparison, Bayesian network meta-analysis…)?", regardless of the answers to the other items. 
